Cyclopharm (ASX:CYC) said that as of Tuesday, its US footprint includes 50 revenue-generating installations, linked to an additional 331 contracted locations, as well as a further 74 primary installations, within the contracting/installation phase, and 48 sites in active contract review, according to a Tuesday Australian bourse filing.
A draft US and international clinical guideline, which recognized its Technegas lung imaging product as a preferred ventilation agent, is expected to be finalized at the upcoming Society of Nuclear Medicine and Molecular Imaging annual meeting in late May.
Its shares jumped 6% in recent trading on Tuesday.